Expression Pathology provides Roche its Liquid Tissue®-SRM Protein Biomarker Assay Services in Drug Development
News Jan 11, 2011
Under the terms of the agreement, Expression Pathology will support Roche oncology drug development programs with multiplexed quantitative assays of cancer signaling pathway proteins and their activation in FFPE tissues by mass spectrometry.
“This new approach to tissue analysis has the potential to dramatically stream-line and improve biomarker identification in FFPE samples during clinical development,” says Dr. Miro Venturi, Senior Biomarker & Experimental Medicine Leader at Roche. “Longer-term, we may envision Expression Pathology’s Liquid Tissue®-SRM platform as becoming a new way of profiling tumors at the molecular level to improve patient stratification and therefore advancing our discovery of personalized medicines.”
“This collaboration with Roche is a key step towards developing valuable clinical assays to improve patient treatment decisions for Roche’s innovative new targeted therapies.” says Casey Eitner, President and CEO of Expression Pathology.
Bioinformatics to Help Understand Intrinsically Disordered ProteinsNews
Over the last several decades, scientists have sequenced 85 million unique proteins, structured and unstructured alike, but still don’t know what the vast majority of these proteins do.READ MORE
Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?News
A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.READ MORE
FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic LeukemiaNews
TheFDA has changed its accelerated approval of blinatumomab (Blincyto®) for some patients with acute lymphoblastic leukemia to a full approval and expanded the approved indications for its use.READ MORE
Comments | 0 ADD COMMENT
Theme: Gathering the Newborn Advances in Cardiology
Mar 19 - Mar 20, 2018